Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: Results of a 12-week, multicenter, non-interventional study

World Journal of Urology

Volumn 29, Issue 2, 2011, Pages 217-223

  Oelke, Matthias ^a   Murgas, Sandra ^b   Baumann, Ina ^c   Schnabel, Frieder ^b   Michel, Martin C ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b APOGEPHA Arzneimittel GmbH   (Germany)

^c Surgery of Urology   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adrenergic antagonists; Cholinergic antagonists; Lower urinary tract symptoms; Overactive bladder syndrome; Propiverine hydrochloride; Urinary retention

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENZILIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; PROPIVERINE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG EFFECT; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MALE; MICTURITION; MIDDLE AGED; MULTICENTER STUDY; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BENZILATES; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY RETENTION; URINATION;

EID: 79953027128     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0654-7     Document Type: Article

References (30)

1. Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milson I, Aiyer LP, Tubaro A, Chapple CR, Wein AJ (2009) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 103(Suppl 3): 12-23.
2. Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJ, Porru D, Thüroff JW (1997) The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms. J Urol 157: 885-889.
3. Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJ, Michel MC (2010) Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol 28: 3-8.
4. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmstein U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21: 167-178.
5. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 54: 419-426.
6. Novara G, Galfano A, Ficarra V, Artibani W (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 50: 675-683.
7. Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z (2006) Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency incontinence. BJU Int 97: 1003-1006.
8. Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z (2006) Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68: 328-332.
9. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 296: 2319-2328.
10. Dmochowski R, Abrams P, Marschall-Kehrel D, Wang JT, Guan Z (2007) Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 51: 1054-1064.
11. Herschorn S, Jones JS, Oelke M, MacDiarmid S, Wang JT, Guan Z (2010) Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology 75: 1149-1155.
12. Saito H, Yamada T, Oshima H, Morita T, Mizuo T, Takeuchi S, Ando M, Sekine H (1999) A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and in combination of propiverine hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jap J Urol Surg 12: 525-536.
13. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, Lee JB, Jeong HJ, Lee T, Park WH (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174: 1334-1338.
14. MacDiarmid SA, Peters KM, Chen A, Armstrong RB, Orman C, Aquilina JW, Nitti VW (2008) Efficacy and safety of extended-release Oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 83: 1002-1010.
15. Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273-2276.
16. Yang Y, Zhao SF, Li HZ, Wang W, Zhang Y, Xiao H, Zhang X (2007) Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J 120: 370-374.
17. Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W (2009) Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. J Urol 182: 2825-2830.
18. Nishizawa O, Yamaguchi O, Takeda M, Yokoyama O (2011) Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. LUTS doi: 10. 1111/j. 1757-5672. 2010. 00081. x.
19. Höfner K, Burkart M, Jacob G, Jonas U (2007) Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 25: 627-633.
20. Höfner K, Burkart M, Jacob G, Jonas U (2010) Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 28: 353-357.
21. Wuest M, Hecht J, Christ T, Braeter M, Schoeberl C, Hakenberg OW, Wirth MP, Ravens U (2005) Pharmocodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol 145: 608-619.
22. 1-adrenoceptors antagonism in human prostate and porcine trigonum. World J Urol. doi: 10. 1007/s00345-011-0655-6.
23. Jünemann KP, Hessdörfer E, Unamba-Oporah I, Berse M, Brünjes R, Madersbacher H, Gramatte T (2006) Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int 77: 334-339.
24. Oelke M, Höfner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H (2007) Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol 52: 827-834.
25. Michel MC, de la Rosette JJ, Piro M, Goepel M (2004) Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J Urol 172: 601-604.
26. Witte LP, Peschers U, Vogel M, de la Rosette JJ, Michel MC (2009) Does the number of previous deliveries affect overactive bladder symptoms and their response to treatment? LUTS 1: 82-87.
27. Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC (2010) Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract 64: 1287-1293.
28. Yamaguchi O (2010) Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 29: 112-115.
29. Blake-James BT, Rashidian A, Ikeda Y, Emberton M (2007) The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99: 85-96.
30. Michel MC, Goepel M (2001) Lower urinary tracts symptoms suggestive of benign prostatic obstruction: what's the long-term effectiveness of medical therapies? Eur Urol. 39(Suppl 3): 20-5.